| |
Total number of patients
|
Fibromyalgia+
|
Fibromyalgia-
|
P
|
|---|
|
(n = 196)
|
(n = 42)
|
(n = 154)
|
|---|
|
Patients who received at least one TNFi
|
141 (71.9 %)
|
33 (78.6 %)
|
108 (70.1 %)
|
0.28
|
|
Number of TNFi treatments
|
1.84 (1.0)
|
2.36 (1.1)
|
1.68 (0.9)
|
<0.01
|
|
Switchers*
|
9 (6.5 %)
|
5 (15.2 %)
|
4 (3.8 %)
|
0.03
|
|
First TNFi
|
|
Mean duration of first TNFi treatment, years
|
3.0 (3.8)
|
1.7 (2.4)
|
3.5 (4.0)
|
<0.01
|
|
Reason for TNFi discontinuation:
|
|
Inefficacy %
|
54 (69.2 %)
|
12 (54.6 %)
|
42 (75.0 %)
|
0.14
|
|
Toxicity %
|
4 (5.1 %)
|
2 (9.1 %)
|
2 (3.6 %)
|
0.76
|
|
Inefficacy + toxicity %
|
4 (5.1 %)
|
3 (13.6 %)
|
1 (1.8 %)
|
0.23
|
|
Others %
|
16 (20.5 %)
|
5 (22.7 %)
|
11 (19.6 %)
|
1.00
|
- All results are presented as mean ± SD for continuous variables or number (%) for categorical variables. Fibromyalgia + was defined as a Fibromyalgia Rapid Screening Tool (FiRST) score ≥5/6. *Patients who received ≥3 TNFi within ≤12 months
